FDA

FDA reports limited availability of tirzepatide, semaglutide injections

February 5, 2024

As of February 5, 2024, FDA's drug shortage website shows that three higher doses of Eli Lilly's diabetes drug Mounjaro (tirezepatide) would be available only in limited amounts through early March 2024, due to increased demand. The agency notes that 10 mg, 12.5 mg, and 15 mg doses of the injection will have limited availability, while lower doses were shown to be available.

Also, FDA reports that Novo Nordisk's Wegovy (semaglutide) injectable drugs—in shortage since March 2022 due to increased demand—continue to have limited availability for the following doses: 0.25 mg, 0.5 mg, 1 mg, and 1.7 mg. There's no additional information on when that shortage will be resolved.

Source:

(Accessed February 5, 2024). FDA. FDA Drug Shortages. https://www.accessdata.fda.gov/scripts/drugshortages/dsp_SearchResults.cfm